Assessment of Grazax® Treatment Compliance

ALK-Abelló A/S500 enrolled

Overview

This trial is performed to assess whether the Grazax® treatment compliance can be improved by use of a compliance device (Memozax®).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Masking

NONE

Enrollment

500

Conditions

Allergy

Interventions

ALK Grass tablet - use of compliance deviceBIOLOGICAL

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Grass pollen induced rhinoconjunctivitis * Males and females, 18-65 years of age * Positive skin prick test Exclusion Criteria: * Previous treatment with grass pollen allergen

Locations (1)

Allgergie - Ambulatorium Rennweg

Vienna, Austria

Outcomes

Primary Outcomes

Assessment of treatment compliance by recording of drug accountability

Secondary Outcomes

Recording of adverse events

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.